Trial Profile
Open-Label, 2-Period, Sequential Design, Exploratory Pharmacokinetic Study In Healthy Subjects to Assess the Pharmacokinetics and Safety of a Supra-Therapeutic Dose of Ibrutinib Capsule and Solution Formulations Administered With Food
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2016
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Breast cancer; Chronic lymphocytic leukaemia; Multiple myeloma; Non-Hodgkin's lymphoma
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 07 Nov 2013 New trial record
- 01 Nov 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.